February 11, 2009
Listen to Audio (5 min.)
Please note: These files can be quite large. Allow some time for them to download.
In this study summary, Elizabeth Stringer, M.D., of the University of Alabama at Birmingham discusses a multi-country cohort study exploring the impact of hormonal contraception on HIV disease progression. After the discussion, there will be a series of questions and answers.
Elizabeth Stringer: There are about 15 million women worldwide who are HIV infected. Most of these women are in childbearing years and they need access to contraception. There are estimated to be 100 million women using hormonal contraception worldwide. Two studies have suggested that hormonal contraception may accelerate HIV disease progression: One was a cohort study in Mombasa, Kenya, and one was a randomized trial we did in Zambia. But this was not the primary outcome of those two studies.
Elizabeth Stringer, M.D.
We also looked at two different hormonal contraceptive groups. One was called progesterone only. This included women using an implant or injectable contraception. Then there was the combined estrogen and progesterone group, which was women using oral contraceptive pills.
We defined HIV disease progression as either becoming eligible for ART [antiretroviral therapy] or death. Then we performed a variety of analyses looking at the impact of different methods of hormonal contraception on HIV disease progression. We performed both crude analysis and multivariable analysis where we controlled for baseline WHO [World Health Organization] stage, age parity, CD4 count, BMI [body mass index] and a host of other factors.
In conclusion, in this large cohort analysis, hormonal contraception appears to be safe in HIV-infected women. But we still believe that more research needs to be done in this area.
Reporter #1: Dr. Stringer, I'm interested to know. This is a largely international population, I think. What proportion were on HAART [highly active antiretroviral therapy]? What's the interaction between hormonal contraception and HAART? Can this be applied? Is this something that we should be thinking about in North America and Europe, as well as in the developing world?
Elizabeth Stringer: For this analysis, women on HAART were excluded. We only looked at women who are ART-naive, and then we looked at their becoming eligible for ART. In the MTCT Plus cohort, ARVs [antiretrovirals] were provided free, so all the women who became eligible were started on ART. I think that may be the more interesting population to look at this in.
It's still yet to be determined if there is an impact of hormonal contraception on HIV disease progression. I think that based on the data we saw presented a couple of days ago on immune activation, there could be an interaction there between hormonal contraception and immune activation -- although this hasn't really been explained in great detail.
Reporter #2: I have a question of whether you had any finer measures of disease progression than just progression to death, or to eligibility.
Elizabeth Stringer: Across the board in the MTCT Plus sites, viral load monitoring was not available, so we don't have information on the impact on viral load.
This transcript has been lightly edited for clarity.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|